Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory
|
By LabMedica International staff writers Posted on 29 Jul 2014 |
|
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Thermo Fisher Scientific Inc. (Waltham, MA, USA) is introducing its Thermo Scientific and Life Technologies (Grand Island, NY, USA) products at the 2014 AACC Annual Meeting and Clinical Lab Expo. Thermo Fisher Scientific Inc. is highlighting its expanded portfolio of instruments, equipment, consumables, and software, for improving accuracy and efficiency in the clinical laboratory.
Marc N. Casper, president and CEO of Thermo Fisher Scientific comments “In the current healthcare environment, our customers in clinical laboratories supporting hospitals, research institutions, and government agencies are increasingly relying on better diagnostics to improve patient care and lower costs. We have the scale and depth of capabilities to help these customers drive accuracy and efficiency and ultimately improve the way healthcare is delivered.”
At AACC, Thermo Fisher will feature a range of products and services from its specialty diagnostics, analytical instrument, and genetic analysis portfolios including complete systems for aiding in the diagnosis of allergy and autoimmune diseases using ImmunoCAP and EliA blood tests such as the DRI Drugs of Abuse Assays, immunosuppressant assays, the CEDIA Cyclosporine Immunoassay, and the QMS Everolimus Immunoassay for therapeutic drug monitoring.
Next-generation sequencing platforms, including the Ion Torrent Personal Genome Machine and the Ion Chef automated sample preparation system for identifying genetic biomarkers of disease are also being shown. A new category of Thermo Scientific products, including high-performance liquid chromatography, mass spectrometry, and software designed and manufactured as US Food and Drug Association (FDA) Class 1 medical devices for use in laboratory-developed tests, and Thermo Scientific calibration and quality controls. In addition, the MAS LabLink Quality Assurance Program, a cloud-based application that offers an external perspective on daily QC and compares the data among peer laboratories will be revealed. Services including original equipment manufacturer (OEM) and custom services for development, manufacturing, and packaging of diagnostic products for third parties, as well as collaborative biomarker research and production services for industry and academia through the Thermo Fisher BRIMS center are introduced.
For a complete listing of products and services being showcased during AACC, please visit Thermo Fisher Scientific online (Please see Related Links below).
Related Links:
Thermo Fisher Scientific
Life Technologies
Marc N. Casper, president and CEO of Thermo Fisher Scientific comments “In the current healthcare environment, our customers in clinical laboratories supporting hospitals, research institutions, and government agencies are increasingly relying on better diagnostics to improve patient care and lower costs. We have the scale and depth of capabilities to help these customers drive accuracy and efficiency and ultimately improve the way healthcare is delivered.”
At AACC, Thermo Fisher will feature a range of products and services from its specialty diagnostics, analytical instrument, and genetic analysis portfolios including complete systems for aiding in the diagnosis of allergy and autoimmune diseases using ImmunoCAP and EliA blood tests such as the DRI Drugs of Abuse Assays, immunosuppressant assays, the CEDIA Cyclosporine Immunoassay, and the QMS Everolimus Immunoassay for therapeutic drug monitoring.
Next-generation sequencing platforms, including the Ion Torrent Personal Genome Machine and the Ion Chef automated sample preparation system for identifying genetic biomarkers of disease are also being shown. A new category of Thermo Scientific products, including high-performance liquid chromatography, mass spectrometry, and software designed and manufactured as US Food and Drug Association (FDA) Class 1 medical devices for use in laboratory-developed tests, and Thermo Scientific calibration and quality controls. In addition, the MAS LabLink Quality Assurance Program, a cloud-based application that offers an external perspective on daily QC and compares the data among peer laboratories will be revealed. Services including original equipment manufacturer (OEM) and custom services for development, manufacturing, and packaging of diagnostic products for third parties, as well as collaborative biomarker research and production services for industry and academia through the Thermo Fisher BRIMS center are introduced.
For a complete listing of products and services being showcased during AACC, please visit Thermo Fisher Scientific online (Please see Related Links below).
Related Links:
Thermo Fisher Scientific
Life Technologies
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Pipet Controller
Stripettor Pro
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
Latest AACC 2014 News
- Corgenix Diagnostic Ebola Test Research Earns Abstract Award
- Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY
- Roche Partners with Customers, Redefines Laboratory Value
- Abbott Showcases Innovations, Helps Labs Solve Health Care Challenges
- Sony DADC BioSciences and TSMC Receive AACC Award
- Oncolab Exhibits Pioneering AMAS Cancer Test at AACC
- Major Advances in Medical Studies Highlighted at AACC 2014
- Wheaton Offers Unique Solutions for the Clinical Market
- Seegene Reveals New Real-Time PCR at AACC 2014
- AACC Debuts Refreshed Brand Identity
- Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting
- EKF Highlights Growing Product Portfolio at AACC 2014 Meeting
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
Technology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
